A mechanism to systematically assess trade agreements from a public health perspective, including accession agreements of the World Trade Organization and European Patent Office’s validation agreements is needed, says Ellen ´t Hoen, senior researcher at the Global Health Unit of the University Medical Centre, Groningen, The Netherlands. who publishes the Medicines Law and Policy website. Continue reading ->
A much cheaper version of a groundbreaking hepatitis C medicine is expected to be available soon for the hundreds of thousands of hepatitis C patients in Malaysia, as it decided to grant a compulsory licence to sofosbuvir, according to sources. The decision comes right after the medicine originator decided to expand its voluntary licensing scheme to four more countries, including Malaysia. [Updated] Continue reading ->
Gilead’s announcement today that they would include four middle-income countries (Malaysia, Thailand, Belarus, Ukraine) in their sofosbuvir voluntary licence was a welcome surprise, and will enable millions access to their highly effective, but exorbitantly priced, drug. The decision to include these countries, however, no doubt is a response to increasing pressure from within these countries to either issue a compulsory licence (CL) or a government use licence (GUL), invalidate the sofosbuvir patents, or block data exclusivity for the drug. Continue reading ->
A United States State Department science envoy quit yesterday in protest over US President Donald Trump's pullout from the Paris climate accord and defensive comments after violence at a white nationalist rally in Charlottesville, Virginia. But according to a press report, Peter Hotez, a past science adviser who has been a featured speaker of a UN agency and pharmaceutical industry group in Geneva, is stepping up to offer his services without concern for Trump's actions. Continue reading ->
The main winners of innovation are technologies that enable market application, with gene editing and artificial intelligence as two examples, Francis Gurry, director general of the World Intellectual Property Organization, told a panel discussion last week. Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), said at the same event that everybody benefits from innovation. Continue reading ->